Novo Holdings-Catalent deal could negatively impact pharma companies, Eli Lilly tells Brazilian regulator
Eli Lilly told the Brazilian competition authority that the acquisition of Catalent by Novo Holdings could impact pharmaceutical companies that depend on the drug manufacturer’s services. Although most of the American...To view the full article, register now.
Already a subscriber? Click here to view full article